Beyond their established role in the treatment of T2DM and obesity, GLP-1 RAs are increasingly being investigated for their therapeutic potential in a broad spectrum of metabolic diseases due to their pleiotropic actions, which affect glucose and lipid regulation, inflammation, and organ function. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.